Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1

AIDS

Volumn 29, Issue 4, 2015, Pages 453-462

  Matsushita, Shuzo ^a   Yoshimura, Kazuhisa ^a,b   Ramirez, Kristel Paola ^a   Pisupati, Jaya ^c   Murakami, Toshio ^d  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c IQVIA   (United States)

^d Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

antibody dependent cell cytotoxicity; escape mutations; HIV 1; mAb; neutralizing antibody; passive immunization

Indexed keywords

NEUTRALIZING ANTIBODY; NEUTRALIZING MONOCLONAL ANTIBODY KD 247; PLACEBO; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BINDING AFFINITY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MALE; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS LOAD; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MULTICENTER STUDY;

ADULT; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MALE; PEPTIDE FRAGMENTS; RNA, VIRAL; VIRAL LOAD;

EID: 84922309399     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000570     Document Type: Article

References (26)

1. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614
2. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4:388-393
3. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med 2012; 2:a007039
4. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Med 2009; 15:951-954
5. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018
6. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, SwiDerek K, Weisgrau KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad SciUS A 2012; 109:18921-18925
7. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-122
8. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228
9. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280
10. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622
11. Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007; 81:1016-11031
12. Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K, Yonemura H, et al. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 2006; 80:5552-5562
13. Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol 2006; 80:5563-5570
14. Zolla-Pazner S. A critical question for HIV vaccine development: which antibodies to induce? Science 2014; 345:167-168
15. Murakami T, Eda Y, Nakasone T, Ami Y, Someya K, Yoshino N, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4R T-cell loss in macaque lymphoid tissue. AIDS 2009; 23:1485-1494
16. Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S. Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate. J Virol 2007; 81:3757-3768
17. Takizawa M, Miyauchi K, Urano E, Kusagawa S, Kitamura K, Naganawa S, et al. Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope. AIDS 2011; 25:2209-2216
18. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 2013; 110:16538-16543
19. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014; 158:1243-1253
20. Hatada M, Yoshimura K, Harada S, Kawanami Y, Shibata J, Matsushita S. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J Gen Virol 2010; 91:1335-1345
21. Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 2006; 20:2065-2073
22. Yoshimura K, Harada S, Boonchawalit S, Kawanami Y, Matsushita S. Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to antienvelope neutralizing antibodies. J Gen Virol 2014; 95: 1816-1826
23. Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, Ochiai C, et al. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 2010; 84:7558-7568
24. Madani N, Princiotto AM, Schon A, LaLonde J, Feng Y, Freire E, et al. CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. J Virol 2014; 88:6542-6555
25. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341:1199-1204
26. Picker LJ, Deeks SG. Antibodies adVance the search for a cure. Nature 2013; 503:207-208